159 related articles for article (PubMed ID: 1458664)
21. Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy.
Pittrof F; Gerhards J; Erni W; Klecak G
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():26-8. PubMed ID: 1458660
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5 % amorolfine lacquer.
Zhang J; Lu S; Huang H; Li X; Cai W; Ma J; Xi L
Lasers Med Sci; 2016 Sep; 31(7):1391-6. PubMed ID: 27339057
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial comparing long-pulsed 1064-Nm neodymium: Yttrium-aluminum-garnet laser alone, topical amorolfine nail lacquer alone, and a combination for nondermatophyte onychomycosis treatment.
Bunyaratavej S; Wanitphakdeedecha R; Ungaksornpairote C; Kobwanthanakun W; Chanyachailert P; Nokdhes YN; Patthamalai P; Tantrapornpong P; Suphatsathienkul P; Kiratiwongwan R; Limphoka P; Leeyaphan C
J Cosmet Dermatol; 2020 Sep; 19(9):2333-2338. PubMed ID: 31925917
[TBL] [Abstract][Full Text] [Related]
24. A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial.
Bassiri-Jahromi S; Ehsani AH; Mirshams-Shahshahani M; Jamshidi B
J Dermatolog Treat; 2012 Dec; 23(6):453-6. PubMed ID: 21781012
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
[TBL] [Abstract][Full Text] [Related]
26. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
27. Scytalidium hyalinum onychomycosis successfully treated with 5% amorolfine nail lacquer.
Downs AM; Lear JT; Archer CB
Br J Dermatol; 1999 Mar; 140(3):555. PubMed ID: 10233295
[No Abstract] [Full Text] [Related]
28. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.
Haria M; Bryson HM
Drugs; 1995 Jan; 49(1):103-20. PubMed ID: 7705210
[TBL] [Abstract][Full Text] [Related]
29. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.
Baran R
Br J Dermatol; 2001 Oct; 145 Suppl 60():15-9. PubMed ID: 11777260
[TBL] [Abstract][Full Text] [Related]
30. A Randomized, Double-blind Study of Amorolfine 5% Nail Lacquer with Oral Fluconazole Compared with Oral Fluconazole Alone in the Treatment of Fingernail Onychomycosis.
Chandra S; Sancheti K; Podder I; Das A; Sarkar TK; Chowdhury M; Sil A; Bhattacharya S; Das NK
Indian J Dermatol; 2019; 64(4):253-260. PubMed ID: 31516132
[TBL] [Abstract][Full Text] [Related]
31. A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails.
Ehrensberger M; Boal CWC; Brennan J; Barrett J; Makarus J; Callanan S; Spillane E; Patton T
J Mycol Med; 2022 Aug; 32(3):101256. PubMed ID: 35219908
[TBL] [Abstract][Full Text] [Related]
32. Comparison of a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer combination therapy versus a 5% amorolfine lacquer monotherapy for the treatment of onychomycosis: a randomized controlled trial.
Zhang J; Zhang Y; Qin J; Lu S; Cai W; Li J; Huang H; Yang S; Xi L
Lasers Med Sci; 2021 Feb; 36(1):147-152. PubMed ID: 32557000
[TBL] [Abstract][Full Text] [Related]
33. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations.
Mensing H; Polak-Wyss A; Splanemann V
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():29-32. PubMed ID: 1458661
[No Abstract] [Full Text] [Related]
34. Dose-finding study of amorolfine cream (0.125%, 0.25% and 0.5%) in the treatment of dermatomycoses.
del Palacio A; Gip L; Bergstraesser M; Zaug M
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():50-5. PubMed ID: 1458666
[TBL] [Abstract][Full Text] [Related]
35. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin.
Friedman-Birnbaum R; Cohen A; Shemer A; Bitterman O; Bergman R; Stettendorf S
Int J Dermatol; 1997 Jan; 36(1):67-9. PubMed ID: 9071624
[TBL] [Abstract][Full Text] [Related]
36. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.
Scher RK; Breneman D; Rich P; Savin RC; Feingold DS; Konnikov N; Shupack JL; Pinnell S; Levine N; Lowe NJ; Aly R; Odom RB; Greer DL; Morman MR; Bucko AD; Tschen EH; Elewski BE; Smith EB
J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S77-86. PubMed ID: 9631989
[TBL] [Abstract][Full Text] [Related]
37. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Ulbricht H; Wörz K
Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
[TBL] [Abstract][Full Text] [Related]
38. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
39. Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.
Iorizzo M; Hartmane I; Derveniece A; Mikazans I
Skin Appendage Disord; 2016 Feb; 1(3):134-40. PubMed ID: 27171791
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
Schaller M; Borelli C; Berger U; Walker B; Schmidt S; Weindl G; Jäckel A
Med Mycol; 2009 Nov; 47(7):753-8. PubMed ID: 19888808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
